7月22日 - ** 制药公司Arrowhead Pharmaceuticals（ARWR.O）的股价在盘前交易中上涨18.1%，至88美元
** 该公司表示，其获批的RNA类药物plozasiran在两项针对更广泛严重高甘油三酯血症（一种血液中脂肪）患者群体开展的晚期临床试验中，达到了主要终点及所有次要终点
** 该药物商品名为Redemplo，在两项研究中，12个月后甘油三酯水平分别降低了79%和81%，而安慰剂组仅降低约27%
** 在各项研究中，Plozasiran还将急性胰腺炎（一种可能致命的胰腺炎症）的发病率降低了78%，并在最高风险患者群体中完全预防了此类事件的发生——ARWR
** 该公司表示未发现新的安全性问题，并计划于年底前申请扩大美国批准范围；详细结果将于8月30日公布
** 截至上一交易日收盘，ARWR今年以来累计上涨12.3%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.